These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey]. Reith S; Klues HG Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787 [TBL] [Abstract][Full Text] [Related]
5. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Sherrid MV; Arabadjian M Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589 [TBL] [Abstract][Full Text] [Related]
6. [Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling]. Coppini R; Ferrantini C; Poggesi C; Mugelli A; Olivotto I G Ital Cardiol (Rome); 2016 Mar; 17(3):189-96. PubMed ID: 27029877 [TBL] [Abstract][Full Text] [Related]
7. The development of familial hypertrophic cardiomyopathy: from mutation to bedside. Brouwer WP; van Dijk SJ; Stienen GJ; van Rossum AC; van der Velden J; Germans T Eur J Clin Invest; 2011 May; 41(5):568-78. PubMed ID: 21158848 [TBL] [Abstract][Full Text] [Related]
19. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Maron BJ; Yacoub M; Dearani JA Eur Heart J; 2011 May; 32(9):1055-8. PubMed ID: 21324934 [TBL] [Abstract][Full Text] [Related]
20. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]